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Abstract  
 
Introduction: The WHO identified Pharmacy and Therapeutics Committees (PTCs) as a pivotal model 
to promote rational medicine use in hospitals. This matches a key South African (SA) government 
objective to establish PTCs in all hospitals to ensure rational, efficient and cost-effective use of 
medicines. However, documentation on the functionality of PTCs in public hospitals in SA is limited. 
This study aimed to address this. Methods:  A 3-phased mixed methods approach involving 
questionnaires, observations of PTC meetings and semi-structured interviews. The findings were 
converged during the interpretation phase. Results: Most professionals were represented in the 
PTCs, with variations across hospitals. Membership of PTCs included a pharmacist, who in the 
majority of cases was the secretary. PTC activities included dissemination of decisions (100%) and 
formulary management (89.5%). However, reporting of ADRs and medication errors was typically 
poor at all hospital levels. Lack of expertise of pharmacoeconomic analysis and evidence-based 
decision-making in formulary management was identified as a key challenge in formulary 
management. Conclusion: Future programmes should strengthen PTCs in specialised aspects of 
formulary management. Further training in the principles of pharmacovigilance is needed at all levels 
to enhance ADR reporting, as well as to ensure compliance with both WHO and provincial guidelines. 
 
1. Introduction 
 
The concept of a pharmacy and therapeutics committee (PTC), also referred to as a drug and 
therapeutics committee (DTC), has been known for decades. However, this committee has become 
substantially more important in recent years with the continued launch of new high cost medicines, 
constrained budgets, and the need to ensure unbiased information for physicians when faced with 
pressures from pharmaceutical companies [1-8]. The beneficial effect of PTCs in monitoring and 
promoting the quality use of medicines, and containing costs in hospital and other institutional 
settings, has been generally accepted in developed countries [9,10]. This has resulted in for instance 
DTCs included in the law in Sweden, with each region in Sweden having at least one DTC [11]. 
However, PTCs either do not exist, or they do not work effectively, in many developing countries 
[9,12,13]. This leads to the irrational use of medicines along with other factors including inadequate 
training of health staff, lack of continuing education and supervision, lack of updated, reliable, 
unbiased drug information and lack of auditing and feedback of prescribing habits. Irrational and 
inappropriate use of medicines can lead to increased hospital admissions and prolonged hospital 
stay, subsequently increasing the cost of healthcare [14]. Effective, safe and economic medicines 
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have to be selected, used and monitored, to ensure high quality therapy at an acceptable price for as 
many people as possible [2,15,16].   
 
The role of PTCs in improving the use of medicines in the community and hospitals is advocated by 
the World Health Organisation [17], and decisions surrounding the management of a formulary 
system should be based on evidence-based principals as well as economic factors to enhance 
optimal care [18]. The base from which members of PTCs can be recruited has widened over time as 
formularies have evolved [10]. A PTC can now include representatives from administration, quality 
assurance groups, and other healthcare professionals and also from user organisations [19]. Overall, 
pharmacists, nurses and the main medical specialists are typically represented in PTCs [14, 19-22]. 
 
There are many possible functions of a PTC, with a key responsibility being to manage the formulary 
system [18, 23, 24]. The PTC must decide which of these functions to undertake as a priority, which 
may depend on local capacities and structures [23].  
 
South Africa published its National Drug Policy (NDP) in 1996, with one of its objectives being to 
establish PTCs in all hospitals in the country to ensure the rational, efficient and cost effective supply 
and use of medicines [25]. To date, we believe no studies have been performed that have addressed 
the composition, functions, and drug selection procedures in PTCs in public hospitals in South Africa. 
However, guidelines have been published both regionally and nationally to try and enhance the 
rational use of medicines in South Africa including guidelines on provincial PTC activities [24]. 
Consequently, this study aimed to describe PTC structures, activities and the medicine selection 
process among public sector hospitals in South Africa to provide a basis for future recommendations.  
 
2. Materials and methods 
 
An exploratory, mixed-methods study with a triangulation design was undertaken. Qualitative and 
quantitative data were collected and analysed separately, but sequentially in three phases, with 
priority given to qualitative data.  
 
6RXWK$IULFD¶VKHDOWKcare system is structured according to four levels of care and referral. Primary 
health care (PHC) is the first level, delivered through the District Health System. Health care services 
are offered at PHC clinics and community health care centers, with pharmaceutical services being 
managed by district pharmacies. Support and referral for health care services at this level of care are 
provided by district hospitals. The second level of care is provided by regional hospitals, from where 
referral can take place to tertiary (academic) hospitals. Central hospitals offer the highest (fourth) level 
of care with specialized hospitals proving care to specialized groups of patients such as at psychiatric 
hospitals. Pharmaceutical services at hospital level are offered by hospital pharmacies with provincial 
pharmaceutical services (Provincial PTCs) overseeing all pharmacy related activities at all levels of 
health care [26, 27].  
 
The study was conducted among public hospitals in the Guateng Province of South Africa. This 
province was chosen as a representative Province for PTC activities with the findings forming the 
basis of future recommendations. At the time of the study, the Gauteng Province had five district 
pharmacies, 13 district hospitals, nine regional hospitals and four tertiary (academic) hospitals (n=31). 
According to the norms and standards for quality service delivery in South Africa, each level of the 
pharmaceutical services is required to have its own PTC [27]. Specialized hospitals were excluded 
from this study, as most did not have active PTCs.  
 
Phase 1 entailed a questionnaire survey being sent to 30 pharmacy managers, who were the 
pharmacy managers of 26 hospitals and five district pharmacies in the Province, One of the academic 
hospitals was excluded from the study as it served as the pilot site for this study. Pharmacy managers 
were targeted for this study as pharmacists were identified as playing an important role in most PTCs 
[13]. The questionnaire was developed based on a provincial circular letter [26], which outlined the 
structure, activities, objectives and medicine selection process for Gauteng Province PTCs. The 
questionnaire consisted of 13 questions contained in the areas of structure, activities and challenges 
with keeping PTCs active. Two of the questions contained 21 sub- questions which required yes or no 
response to pre-coded categories. A question regarding challenges encountered by pharmacists in 
keeping the PTC active was open ended (Appendix 1). Questionnaires were either emailed or faxed 
to the pharmacists. Responses to the questionnaires were followed-up two weeks after being emailed 
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or faxed, until all responses had been returned. On receipt, incomplete questionnaires were set aside 
and excluded from the final analysis. 
 
Non-participatory observations of the meetings of 13 PTC meetings followed this between June 2011 
and June 2013 in Phase 2. Observations were carried out only in those institutions which gave 
permission to conduct the study at their site. In total, 26 PTC meetings were observed. This meant 
that in some PTCs, more than one meeting was observed for the purpose of reaching data saturation. 
Observed PTC meetings were also typically audio recorded for later transcription, except for a few 
cases where consent was not given. In these cases, detailed notes were taken of the meeting and 
proceedings, and later compared with the minutes of the meeting to ensure accuracy and 
trustworthiness.  
 
The gaps identified in the first two phases were addressed in Phase 3 through non-structured in-depth 
interviews with nine pharmacy managers who consented to be interviewed between October 2013 
and March 2014. Seven of these pharmacists (one from a tertiary hospital and three from district and 
regional hospitals respectively) were hospital-based and two were from district pharmacies. Two of 
the interviews were conducted with pharmacy managers whose PTCs were not active. The interviews 
were conducted in a private room DWWKHSDUWLFLSDQW¶VIDFLOLW\were audio recorded for later 
transcription, and typically lasted approximately 30 minutes 
 
Descriptive statistics were used to summarise Phase 1 survey results, using frequency counts and 
percentages. Transcribed data from Phases 2 and 3 were analysed using NVivo9®. Data were coded 
into categories and developed into a framework of themes. Results from the different phases were 
converged during the interpretation phase. Phase 1 survey results were compared to the themes 
identified from observations (Phase 2) and interviews (Phase 3) to confirm actual PTC structures and 
activities.  
 
Ethical clearance for the study was obtained from the Medunsa Research Ethics Committee of the 
University of Limpopo (now Sefako Makgatho Health Sciences University) (MREC/H/170/2010:PG) 
and permission granted by provincial authorities. All participants provided written informed consent. 
 
3. Results 
 
Table 1 shows the sample for each phase of the study as well as the hospital level of care for the 
relevant PTC or pharmacist. The overall response rate for the survey in Phase 1 was 76.6% (23 out of 
30). Three questionnaires were incomplete and, as mentioned, were subsequently excluded from the 
data analysis, making a final sample size of 20. One of the 20 responding pharmacists indicated that 
their PTC was inactive at the time of the survey; however, some of the responses from this 
questionnaire were included in the final analysis.  
 
The provincial PTC was not included in Phase 1 as it was inactive at the time of the survey. However 
at the time of Phase 2, it had been revitalized and consequently was included in Phase 2. 
 
Table 1: Final sample and hospital level of care for each of the three phases of the study 
 
Level of care Phase 1 Pharmacist 
Survey 
Phase 2 PTC 
Observation 
Phase 3 Interviews 
District hospital 9 3 3 
Regional hospital 6 4 3 
Tertiary hospital 2 3 1 
District PTC 3 2 2 
Provincial PTC 0 1 - 
Total  20 13 9 
NB. The provincial PTC was not included in Phase 1, as it was inactive at that stage and in Phase 3, as it was 
constituted by members who served at lower level PTCs. It was however included in Phase 2, as it had been 
revitalised at that stage of the study. 
 
As seen in Table 1, in Phase 2 PTC meetings were observed at 13 out of the 20 hospitals, with 
representation from all levels of care. At some of the hospitals, more than one PTC meeting was 
observed which resulted in a total of 26 observations. 
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3.1 Quantitative findings - Phase 1 
 
3.1.1 Structure of the PTCs 
 
3.1.1.1 Meetings 
PTC meetings in this study varied between monthly to quarterly per year (see Figure 1). Seventy five 
percent of regional hospitals met once a month and both the tertiary hospitals met once a month. All 
the other institutions were within the Gauteng provincial specifications [26] as they met once a month 
or quarterly. 
 
Figure 1: Frequency of PTCs meetings among the various hospitals in Gauteng Province (n=20) 
 
 
 
Table 2 shows the categories of professionals represented in the surveyed PTCs.  
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Table 2: Categories of professionals represented in the PTCs 
 
Categories of 
professionals 
Pharmacy and Therapeutics Committees (PTCs) 
District 
Hospital  
(n=9) 
Regional 
Hospital 
(n=6) 
Tertiary 
Hospital 
(n=2) 
District 
PTC (n=3) 
Total (N=20) 
Clinical Experts 
Specialist 
representing the 
major disciplines  
9 5 2 1 17 
Clinical 
Pharmacology 
3 0 2 0 5 
Head of Pharmacy  
School 
0 0 0 0 0 
Nursing 
representatives 
7 4 0 3 14 
Clinical 
Microbiology 
1 0 2 1 4 
Clinical Directors  0 0 2 0 2 
Secretariat 
 
6 2 1 2 11 
Financial Director 
(or representative 
of the finance 
department) 
3 4 2 2 11 
 
Overall, 85% of the committees had clinical specialists as members. Clinical Directors from academic 
hospitals were represented in 10% of the PTCs, with 100% representation at the tertiary hospital 
PTCs and no representation at the district PTCs, district hospital and regional hospital PTCs. The 
tHUWLDU\KRVSLWDO¶V37&VZHre the only ones that did not have representation from nursing, whereas in 
all the other PTCs nursing was represented in more than 70% of the committees. Fifty five percent of 
the pharmacists were the secretariat of their respective committees. 
 
3.1.1.2 Subcommittees 
 
In the survey, pharmacists indicated that four of the 20 PTCs had a formulary subcommittee (20%); 
five (25%) had an ADR sub-committee, seven (35%) had an antimicrobial subcommittee, and 18 
(90%) had infection control subcommittees. Nine hospitals (45%) had other subcommittees, which 
included a blood and blood products committee and a quality assurance committee.  
 
3.1.1.3 Activities of PTCs 
The activities of the PTCs are summarised in Table 3. 
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Table 3: Activities performed by PTCs at the different levels of care 
 
ACTIVITIES* District 
Hospital PTC 
(n=9) 
Regional 
Hospital 
(n=5) 
Tertiary 
Hospital 
(n=2) 
District PTC 
(n=3) 
Total (%) (N 
19) 
Dissemination decisions of 
the committee to all staff 
members 
9  5  2  3  19 
Formulation of policies and 
guidelines pertaining to the 
use of medicines within the 
hospital 
8  5  2  3  18  
Developing formularies 9  3  2  2  17 
Monitoring of expenditure on 
medicines; ensure that it is 
in line with current budgets 
to maintain rational and 
cost-effective prescribing 
practices. 
7  5  2  3  17 
Drafting and coordinating  
implementation of  treatment 
guidelines 
6  4  2  2  14 
Ensure a proper down 
referral system  
9  3  0 2  12 
Carry out medicine 
utilization evaluation 
6  4  1  0 11 
Develop and enforce 
standard guidelines for 
company representative 
4  3  2  2  11 
Supporting research 
activities by reviewing 
protocols and evaluating 
data relating to new 
medicines used in the 
hospitals 
5  4  2  1  10  
Review the National 
Treatment Guidelines 
6  2  2  1  11 
Initiation of educational 
programmes in matters 
relating to drug therapy 
6  2  0 2  10 
Preparation of new standard 
treatment guidelines where 
applicable 
4  1  2  2  9 
Collecting and processing 
reports of adverse drug 
reactions. 
4  1  1  1  7 
*Activities of PTCs as stipulated in Circular 27 [26] 
 
According to the survey, dissemination of PTC decisions to all staff was carried out by all of the PTCs. 
This was followed by formulation of policies and guidelines performed by 94.7% of the PTCs, and 
formulary development and monitoring expenditure on medicines carried out by 89.4% of the PTCs 
(Table 3).  
 
The least performed activities were the collection and processing of ADRs and development and 
enforcement of guidelines for company representatives (36.8%). 
 
3.1.1.4 Challenges to PTC activity 
Many factors contribute to the success of the PTCs. The challenges encountered by pharmacists in 
keeping PTCs active are presented in Figure 2. Lack of staff was a challenge encountered by 35% of 
the pharmacists, followed by poor attendance of meetings (30%), poor communication of decisions 
(20%) and lack of time allocated for meetings (20%). 
 
  
7 
 
Figure 2: Challenges to the activity of PTCs 
 
 
3.2 Qualitative findings ± Phases 2 and 3 
 
These were derived from observation of 26 PTC meetings and 9 semi- structured interviews. 
 
3.2.1 Subcommittees 
The only subcommittee which seemed to be active or in the process of being formulated among the 
PTCs in the study was the antimicrobial stewardship committee, specifically at tertiary level PTCs and 
only one regional level PTC.  
 
The provincial PTC was the only committee that had active subcommittees, which were observed to 
be (1) Safety and Quality Subcommittee and ADR reports, (2) Medicine Rational Utilisation 
Subcommittee, (3) Formulary Subcommittee, and (4) Procurement Advisory Subcommittee. 
In addition to the formal subcommittees as observed, two other programmes namely the National 
Health Laboratories (NHLS) and Expanded Programme on Immunisation (EPI) were represented 
during PTC meetings, especially the district PTCs and in one district hospital. These two programmes 
featured at PTC meetings for various reasons. One of the pharmacists in Phase 3 of the study 
explained that the presence of the NHLS was to contain the costs of laboratory services: 
 
³The laboratory and blood services were no part of the PTC previously but a directive to incorporate 
them into the PTC came from the province. I think there were a lot of challenges in terms of blood 
tests done at different levels with respect to cost, monitoring of expenditure, and appropriate blood 
tests for appropriate level of care´[District  pharmacist] 
 
3.2.2 Activities of PTCs 
Pharmaceutical budgets were discussed at all observed PTC meetings. The main discussions 
revolved around budget allocation which was deemed to be inadequate in most instances: 
³The fact that pharmacy managers never receive amounts they request for their budget was seen as 
a challenge. Although the requested budget is not allocated pharmacy is still expected to deliver a 
service of high quality´. [Observation Provincial PTC] 
 
In contrast to the survey results, it was evident during the observations of PTC meetings that 
formulary management was carried out in all (13) PTCs. It was also evident that more than half of the 
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PTCs reviewed their formulary lists on a regular basis. Other discussions dealt with the rationale for 
the addition of new medicines, which was typically based on their costs and the clinical evidence. Five 
of the PTCs approved the addition of new medicines into their formularies, and removed some 
medicines from the formulary during the observed meetings. Variation in the application and/ or 
motivation for the addition of new medicines at the different institution was also observed.  
 
In addition to formulary management, management of medicine shortages was observed to be the 
second highest activity which the PTCs were involved with, as this was on the agendas of all PTCs 
with the exception of the Provincial PTC.  
 
The PTCs also appeared actively involved with ABC analysis of priority areas to concentrate on in line 
with WHO recommendations [23], i.e. the top 20 medicines with the highest expenditure. ABC 
analysis is a well accepted method for prioritising key medicines to concentrate on based on their 
annual usage and costs [28]ZLWKµ$¶UHIHUULQJWRKLJKFRVWLWHPVµ%¶UHIHUULQJWRPHGLXPFRVWLWHPV 
DQGµ&¶UHIHUULQJWRORZFRVWLWHPV An ABC analysis was used as a basis to carry out medicine 
utilisation reviews in at least one of the PTCs, as illustrated by the discussion: 
³:HKDYHGRQHWKDW08(RQWKHXVHRIDQWLELRWLFVEHFDXVHDQWLELRWLFXVHLV very high; third line 
DQWLELRWLFVRIWHQDSSHDULQWKHWRSWHQLWHPVRIRXU$%&DQDO\VLVEHFDXVHWKH\DUHH[SHQVLYH´[tertiary 
hospital pharmacist] 
 
3.2.3 Formularies 
 
Four of the nine pharmacists interviewed indicated that they did not have a hospital specific formulary 
list or manual. All of these pharmacists indicated that they used the current South African EML as a 
point of reference, as illustrated by the pharmacist at a district hospital: 
³Our formulary is guided by the EML, so we take the EML as our formulary. If the doctors ask for an 
item, we first check if it is an EML item. If it is, we know that we have to keep it´[District pharmacist] 
 
However, it was not evident how dissemination of the PTC decisions was carried out (Phase 2 and 3). 
During the Phase 3 interviews, pharmacists indicated that this was typically undertaken through 
FLUFXODUOHWWHUVRUSHUVRQDOFRPPXQLFDWLRQE\WKHFRPPLWWHHV¶PHPEHUVFrom the observations 
(Phase 2), it was evident that ADR reporting was indeed poor since in most PCT meetings, despite 
typically being on the agenda, no reports were presented.  
 
3.2.4 Challenges to PTC activity 
Follow-up interviews confirmed that the lack of staff and competing priorities of PTC members, which 
also contributed to the poor attendance at PTC meetings:  
³7KHELJJHVWFKDOOHQJHLVFRPSHWLQJSULRULWLHVRWKHUPHHWLQJVWUDLQLQJDQG,WKLQNDELJJDSIRUXVLV
that there is a lack of doctors.´[Regional hospital pharmacist] 
 
Potential reasons included the high turnover of staff. In addition the lack of support of the committees 
from clinicians due to other commitments: 
³There are a lot of meetings and if you have to have all those doctors in all meetings it would not be 
possible´. [Regional hospital pharmacist] 
³The PTC was not compliant, for example, there was no representative of the doctors, and we did not 
get any response from the district medical officer´. [District hospital pharmacist] 
 
The lack of expertise in pharmacoeconomics and evidence-based decision-making was also identified 
as one of the challenges in formulary management. Survey results and interviews with pharmacists 
revealed that insufficient staff and poor attendance of meetings hindered PTC activities. 
 
4. Discussion 
 
The study highlighted variations among the different PTC levels in the way they were structured, and 
in their approaches to formulary management. Concerns are important to address given the high 
prevalence of infectious diseases as well as non-communicable diseases in South Africa, including 
hypertension and obesity, which is growing adding to the cost public health cost burden [29-34]. 
Encouragingly, the activities of the PTCs in the Gauteng Province were similar to the stipulations in 
both WHO [23] and the Provincial Guidelines [24]. However, concerns in a number of areas which 
need to be addressed. 
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4.1 Meetings 
 
Encouragingly, the majority of PTCs met on average once monthly. This compares with typically lower 
rates in a number of other countries, e.g. 37.5% of PTCs met quarterly and only 25% met monthly 
among Sudanese hospitals [14]. In Spain, there was a mean of 5.1 meetings per year [21], in 
Denmark two to six per year [20], and in Canada 8.2 times a year on average in hospitals with 300 or 
more beds [21].  
 
However, there was limited representation by clinical directors in the PTCs, which could be attributed 
to the fact that the survey asked for clinical directors of academic hospitals, which were only 
represented by two hospitals. Clinical Microbiology was represented in 20% and clinical 
pharmacologists in 25% of the PTCs, which was similar to hospital PTCs in the Netherlands. 
However, Clinical Pharmacologists play a greater role among DTCs in Stockholm County in Sweden 
[3,35]. When considering a specific level of care, both tertiary hospitals had representation from 
clinical pharmacologists, which is important to train specialists.  
 
Studies conducted in Denmark and the Netherlands showed that nurse representation was much 
lower compared to this study (70%) and varied from 7% to 29% of hospital PTCs [20]. Low 
representation was also seen in Thailand [36]. 
 
In this study, positions held by pharmacists were seen in all the PTCs, which is in line with the 
provincial guidelines. This is important as they are trained to provide expert advice on the evaluation 
of new medicines alongside clinical pharmacologists. They are also knowledgeable in areas such as 
therapeutic equivalence and they are often responsible for managing the medicines budget [21].  
 
4.2 Subcommittees  
 
PTCs often have subcommittees to address particular issues and assist with the complexities of 
decision making [23, 37].  The antimicrobial stewardship committee was the most active 
subcommittee in our study (35%). This is encouraging given concerns with the extent of antimicrobial 
resistance (AMR) in hospitals in South Africa and the recent Department of Health initiatives to reduce 
AMR [38,39]. Most hospitals (45%) also had other subcommittees in addition to those stipulated in the 
Provincial guidelines. 
 
Studies on the structure and operation of PTC in other countries also indicated that in some hospitals 
PTCs worked alongside other committees [20,40].  
 
4.3 Activities 
 
Formulary management was observed to be the main activity carried out by all PTCs. This is 
welcomed as South Africa has developed treatment guidelines that can be used when developing 
hospital formularies [24]. This is similar to a national survey in the US where 99.6% of hospitals and 
health-system PTCs were responsible for formulary development and management including drug 
policy development [41], with similar findings in other studies [9,14, 42].  
 
Even though dissemination of PTC decisions was indicated as one of the main activities of the PTCs 
in Phase 1 (Table 3), this was not evident from Phase 2. This was also seen by Tan et al. [43], who 
upon reviewing PTC minutes, found no action appeared to be taken to implement or follow up on 
some PTC decisions. This is a concern as inadequate dissemination of information leads to a loss of 
credibility and limited effectiveness of PTCs. 
 
The second activity that PTCs were mostly involved with was the management of medicine shortages. 
This is a concern since according to WHO [23], a PTC often has to coordinate with those responsible 
for procurement and distribution of medicines to help ensure patients have access to the most 
appropriate medicines. Efforts should be made to avoid PTCs becoming a forum for only making 
procurement decisions and managing stock outs [23]. Having said this, shortages should be part of 
the agenda for PTCs [23], with PTCs developing contingency plans to prepare for possible prolonged 
shortages as part of good medicine management. This can be part of monitoring of expenditure and 
medicine use, with expenditure monitoring carried out by 89% of the PTCs in this study with 
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discussions on budget allocation and expenditure taking place in five of the observed 13 PTC 
meetings.  
 
The main concern at all PTCs was insufficient funding for medicines, similar to other countries [42]. 
The current trend in budgeting is to decentralise budgets down to the point of service, since those 
rendering the service are usually more aware of specific circumstances and conditions, as seen 
across countries despite concerns [44-46]. However, this approach had not yet been adopted by the 
Province, with almost all levels of PTCs complaining about their lack of involvement in determining 
budget allocation.  
 
Aggregate drug utilisation data can be used to conduct ABC analysis and therapeutic category 
analysis to help PTCs better manage their formulary medicines list and identify problems [23]. This is 
also a concern since in our study only three PTCs in Phase 2 were undertaking such activities.  
 
PTCs also have a major role in ensuring that all medicines are prescribed, dispensed and 
administered to patients in as safe a way as possible, and that all medicines are of adequate quality. 
As a result, help to ensure appropriate use of resources. Consequently, one of the functions of PTCs 
should be to oversee the monitoring, tracking and accounting of adverse drug reactions as 
documented in the Guateng Province guidelines [24,26]. However in this study, one of the least 
performed activities was the collection and processing of ADRs, similar to other countries and settings 
[47]. This is a concern as evidence of a clear pharmacovigilance system to monitor and manage 
ADRs is a requirement for compliance with the National Core Standards [48]. Measures to increase 
ADR reporting include education of health professionals of its importance, reporting forms being 
readily available and the use of electronic reporting, which have all been found to be effective 
elsewhere [48-50], and have shown to be a possibility among public hospitals in  South Africa [51].  
 
Overall, the success of a PTC depends upon it being active and working regularly in a consistent 
direction [23]. However, poor communication of decisions and lack of time allocated for meetings 
were seen in our study. Lack of expertise on applying evidence-based decision-making in formulary 
management was also identified as one the main challenges among PTCs, similar to other countries 
[9, 22,52]. The lack of expertise can be addressed by bringing together various specialists from 
different disciplines to compile suggested medicines for different disease states, building on 
experiences in other countries [3,35]. In this way, PTCs become a learning organisation to benefit the 
hospital in the future.  
 
We believe the mixed method approach to data collection in our study enable the principal researcher 
(MM) to explore the activities and functions of PTCs in Gauteng Province in detail as well as the 
challenges of keeping PTCs active. We also believe the sample of hospitals chosen was 
representative of the wide spectrum of PTC levels in the Province adding robustness to our findings 
and suggested future activities. Future programmes should strengthen PTCs in specialised aspects of 
formulary management, building on the replies of the participants. This includes pharmacoeconomics 
in addition to evidence based medicine. Strong institutional support should be encouraged, along with 
adequate funding, to ensure better participation in PTC activities to enhance rational medicines use 
among public sector hospitals in South Africa. This acknowledges that membership of PTCs is 
typically voluntary and members generally have several other roles [23]. However, appropriate 
management of medicines should be the responsibility of all to ensure good use of available 
resources with ever growing pressure on resources in South Africa. Resources should also be made 
available to support auditing of the PTCs activities, which can involve the development of an indicator 
checklist. 
 
We are aware that we only undertook this study in one Province in South Africa. However, we believe 
in view of the comprehensive approach we adopted and the careful choosing of the Province that the 
findings will be applicable to other hospitals in South Africa. We will be following this up in future 
research.  
 
Conclusion 
 
We believe this is the first study in South Africa that has looked at the structure, activities and 
functions of PTCs in public hospitals. Positively PTCs in the public hospitals in South Africa were 
active in the majority of the hospitals, with their structure and activities similar to the stipulations from 
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both WHO and the Provincial Guidelines, which is encouraging. Their main activities evolved around 
formulary management, with variation among the different levels of care, with the tertiary and 
provincial hospitals using more evidence based approaches when selecting medicines for the 
formulary.  However challenges exist including adequate resourcing, undertaking drug utilisation 
activities to monitor and improve medicine use, lack of ADR reporting and the lack of expertise in 
evidence based decision making. These are opportunities to strengthen PTC activities and functions 
in South Africa by learning from other countries. Similar studies can be carried out in other Provinces 
in South Africa to assess the generalizability of our findings. Other studies should also be undertaken 
to explore the areas of concern in our study particularly around promoting and ensuring the rational 
use of medicines. We will be monitoring this in the future. 
 
Key points: 
x There are a number of possible functions of PTCs. The National Drug Policy in South Africa has 
as an objective that PTCs should be established in all hospitals the rational and efficient use of 
medicines as well as cost-effective supply 
x There have been a number of guidelines in South Africa to enhance the rational use of medicines 
including guidance on PTC activities. However despite this, the structure and function of PTCs in 
Gauteng Province varied greatly 
x Pharmacists were typically involved in PTC activities, with principal activities of PTCs involving 
formulary management and dissemination of decisions 
x Identified concerns included current budget allocation, lack of ADR and medical error reporting as 
well as a lack of evidence-based decision making 
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